Sio Capital Management LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT)

Sio Capital Management LLC acquired a new position in ADC Therapeutics SA (NYSE:ADCT) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,160,632 shares of the company’s stock, valued at approximately $4,213,000. ADC Therapeutics makes up 2.1% of Sio Capital Management LLC’s portfolio, making the stock its 10th biggest holding. Sio Capital Management LLC owned about 2.81% of ADC Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Prospera Financial Services Inc purchased a new position in ADC Therapeutics in the first quarter worth $25,000. HRT Financial LP purchased a new position in shares of ADC Therapeutics in the first quarter valued at $31,000. Quantbot Technologies LP purchased a new position in shares of ADC Therapeutics in the second quarter valued at $38,000. Tower Research Capital LLC TRC increased its position in shares of ADC Therapeutics by 1,253.3% in the third quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $46,000 after buying an additional 8,773 shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its position in shares of ADC Therapeutics by 1,270.5% in the first quarter. Advisor Group Holdings Inc. now owns 3,248 shares of the company’s stock valued at $47,000 after buying an additional 3,011 shares in the last quarter. Hedge funds and other institutional investors own 67.29% of the company’s stock.

ADC Therapeutics Trading Down 1.8 %

ADC Therapeutics stock opened at $1.07 on Friday. The stock has a market cap of $82.19 million, a PE ratio of -0.47 and a beta of 1.01. The stock has a 50-day moving average price of $1.49 and a 200 day moving average price of $2.09. ADC Therapeutics SA has a 52 week low of $1.05 and a 52 week high of $6.58. The company has a current ratio of 5.12, a quick ratio of 4.88 and a debt-to-equity ratio of 2.57.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). The company had revenue of $19.28 million for the quarter, compared to analysts’ expectations of $34.77 million. ADC Therapeutics had a negative return on equity of 325.79% and a negative net margin of 98.33%. Equities research analysts predict that ADC Therapeutics SA will post -2.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ADCT shares. JPMorgan Chase & Co. upgraded ADC Therapeutics from an “underweight” rating to a “neutral” rating in a research report on Thursday, August 10th. Morgan Stanley dropped their price target on ADC Therapeutics from $5.00 to $2.00 in a research report on Tuesday, July 11th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of ADC Therapeutics in a research report on Tuesday, July 25th. Finally, Royal Bank of Canada dropped their price target on ADC Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, ADC Therapeutics currently has a consensus rating of “Hold” and an average target price of $7.83.

ADC Therapeutics Company Profile

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL).